Results 21 to 30 of about 11,492 (193)
Incretin-based therapies for cardio-kidney-liver-metabolic disease: the role of the liver in the modern era of chronic disease management [PDF]
Clinical and Molecular HepatologySteatotic liver disease (SLD) is a leading cause of disease globally and demands new therapeutic approaches to mitigate underlying metabolic dysregulation. Incretin-based therapies are emerging as a viable prospect to fulfil this unmet niche.
Harendran Elangovan +7 more
doaj +1 more source
The Potential Role of Platelet Indices and Red Cell Distribution Width in Metabolic Dysfunction-Associated Fatty Liver Disease [PDF]
African Journal of Gastroenterology and HepatologyBackground:Hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and even hepatocellular carcinoma are all possible outcomes of metabolic dysfunction-associated fatty liver disease (MAFLD).
Shimaa Mansour +4 more
doaj +1 more source
Frontiers in Endocrinology, 2022 Background and aimsThe epidemiological characteristics of MAFLD and its relationship with atrial fibrillation (AF) are limited in China. Therefore, we explored the epidemiological characteristics of MAFLD from adults along with the association of MAFLD ...
Fang Lei +43 more
doaj +1 more source
Metabolic dysfunction-associated fatty liver disease in people living with HIV
Scientific Reports, 2023 The prevalence of metabolic risk factors and non-alcoholic fatty liver disease (NAFLD) is high among people living with HIV (PLWH). Data on the recently proposed definition of metabolic dysfunction-associated fatty liver disease (MAFLD) in PLWH receiving
Maurice Michel +8 more
doaj +1 more source
Diabetes, Metabolic Syndrome and Obesity, 2023 Jia Pan,1,* Bo Yang,1,* Zihang Wang,2 Lei Tang,1 Peng Jia,3,4 Shujuan Yang,1,2,4 Honglian Zeng1 1Department of Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu University, Chengdu, Sichuan, People’s Republic of China;
Pan J +6 more
doaj
Cardiovascular Diabetology, 2023 Background Data are limited on the association of metabolic dysfunction-associated fatty liver disease (MAFLD) with systemic atherosclerosis. This study aimed to examine the relationship between MAFLD and the extent of atherosclerotic plaques and ...
Yanli Zhang +14 more
doaj +1 more source
Frontiers in Endocrinology, 2022 BackgroundA number of epidemiological studies have suggested an association between metabolic dysfunction-associated fatty liver disease (MAFLD) and the incidence of atrial fibrillation (AF).
Raphaël Decoin +23 more
doaj +1 more source
Molecular Aspects of MAFLD—New Insights on Pathogenesis and Treatment
, 2023 Metabolic-associated liver disease (MAFLD) affects up to 70% of overweight and more than 90% of morbidly obese people, and its pathogenesis is rather complex and multifactorial. The criteria for MAFLD include the presence of hepatic steatosis in addition
Dragana Mijac +8 more
core +1 more source
Annals of MedicineBackground Fibrotic metabolic dysfunction-associated steatohepatitis (MASH) is a condition at risk of progressing to advanced liver disease. We examined whether an innovative exhaled nitric oxide (eNO) breath test (BT) can accurately diagnose fibrotic ...
Huai Zhang +11 more
doaj +1 more source
Associations remnant cholesterol and insulin resistance with metabolic-associated fatty liver disease [PDF]
Romanian Journal of Medical PracticeBackground. Remnant cholesterol (RC), a component of triglyceride-rich lipoproteins, has recently gained attention as an emerging metabolic and cardiovascular risk factor.
Taufik BIYA +2 more
doaj +1 more source